IL6 and neoplasm: Indeed, given the previously proposed decoupled effect of IL-6 blockade in enhancing both anti-tumor and anti-inflammatory responses, several clinical trials have been initiated in recent years to evaluate the efficacy and safety of IL-6-targeting therapies in patients undergoing ICI treatment (20).